The targeted therapy for 4 eosinophil-driven diseases
- add-on maintenance treatment of patients 6 years and older with SEA. NUCALA is not for the relief of acute bronchospasm or status asthmaticus.
- add-on maintenance treatment of CRSwNP in adults 18 years and older with inadequate response to nasal corticosteroids.
- treatment of adult patients with EGPA.
- treatment of patients aged 12+ with HES for ≥6 months without an identifiable non-hematologic secondary cause.
NUCALA reduced blood eosinophils and maintained within normal levels across indications.1-3
Note: Mean normal blood eosinophil levels in a general population of subjects without confounding factors have been reported as 100 cells/µL (range: 34-257) and 107 cells/µL (5th, 95th percentile: 30, 395); levels vary based on age, sex, environmental exposures, and comorbid conditions.4-5
NUCALA is covered for 98% of SEA commercial patients nationallyFormulary status may vary and is subject to change. Formulary coverage does not imply clinical efficacy or safety. This is not a guarantee of partial or full coverage or payment. Covered: Any potential for reimbursement from a health plan and may include step edits, prior authorizations, and other restrictions.
Medical benefit coverage as of August, 2021. Individual access may vary by geography, formulation, and plan benefit design. “Patients” means covered lives for all commercial and employer payer types (excluding Managed Medicaid) as calculated by Managed Markets Insight & Technology (MMIT), LLC.6